

<b>Index of Exhibits</b>	
Exhibit A	U.S. Patent Nos. 5,441,868
Exhibit B	U.S. Patent Nos. 5,547,933
Exhibit C	U.S. Patent Nos. 5,618,698
Exhibit D	U.S. Patent Nos. 5,621,080
Exhibit E	U.S. Patent Nos. 5,756,349
Exhibit F	U.S. Patent Nos. 5,955,422
Exhibit G	Expert Declaration of Thomas R. Kadesch, Ph.D., Professor of Genetics at the University of Pennsylvania School of Medicine, and attached exhibits.
Exhibit H	May 5, 1999, Amendment, 08/100,197-33.
Exhibit I	Goldwasser Depo. Tr. February 14, 2007
Exhibit J	March 31, 1995, Office Action, 08/100,197-26
Exhibit K	February 10, 1989, Office Action, 07/113,178-9.
Exhibit L	June 2, 1989, Amendment Under Rule 116, 07/113,178-11
Exhibit M	May 24, 1988, Second Preliminary Amendment, 07/113,179-8.
Exhibit N	September 1, 1993, Office Action, 07/113,179-29.
Exhibit O	January 10, 1994, Amendment and Response, 07/113,179-33.
Exhibit P	Brief for Lin in Interference No. 102,097.
Exhibit Q	U.S. Patent No. 4,399,216.
Exhibit R	MANUAL OF PATENT EXAMINING PROCEDURE § 2173.05(h) I.
Exhibit S	MANUAL OF PATENT EXAMINING PROCEDURE § 608.01(p) Completeness [R-3].
Exhibit T	February 27, 2007 Letter From Thomas Fleming to Deborah E. Fishman.
Exhibit U	U.S. Patent No. 4,703,008.
Exhibit V	U.S. Patent No. 6,583,272.
Exhibit W	Pollack, A., "Rivals Laying Siege to Amgen's Near Monopoly in Anemia Drugs," The New York Times, Dec. 23, 2005.
Exhibit X	November 30, 1984, Application No. 06/675,298.
Exhibit Y	June 16, 1986, Office Action, 06/675,298-8.
Exhibit Z	June 18, 1987 Office Action, 06/675,298-17.
Exhibit AA	July 10, 1987, Amendment and Reply, 06/675,298-20.
Exhibit BB	October 23, 1987, Application No. 07/113,178.
Exhibit CC	June 2, 1988, Office Action, 07/113,178-4.
Exhibit DD	June 2, 1989, Amendment Under Rule 116, 07/113,178-11.
Exhibit EE	June 20, 1989, Office Action, 07/113,178-13.
Exhibit FF	July 12, 1989, Amendment, 07/113,178-15.
Exhibit GG	December 12, 1989, Examiner Interview, 07/113,178-17.
Exhibit HH	January 1, 1990, Amendment Under Rule 116, 07/113,178-19.
Exhibit II	May 24, 1988, Second Preliminary Amendment, 07/113,179-8.
Exhibit JJ	September 27, 1988, Applicant's Reply, 07/113,179-14.
Exhibit KK	Goldwasser Depo. Tr. February 14, 2007
Exhibit LL	Morgan Stanley Equity Research, "Amgen: Some Setbacks for Competitors in EU," Feb. 26, 2006.

Exhibit MM	<i>Amgen Inc. v. Hoechst Marion Roussel Inc.</i> , No. 97-10814 (D. Mass.), Trial Tr. (June 7, 2000).
Exhibit NN	MANUAL OF PATENT EXAMINING PROCEDURE § 2111.03 [R-3].
Exhibit OO	THE AMERICAN HERITAGE DICTIONARY 1399 (4th ed. 2006).
Exhibit PP	Supplemental Expert Declaration of Thomas R. Kadesch, Ph.D., Professor of Genetics at the University of Pennsylvania School of Medicine, and attached exhibits.
Exhibit QQ	December 11, 1996, Interview Summary, 0-8/468,381-7.
Exhibit RR	J. C. Egrie et al., <i>Characterization and Biological Effects of Recombinant Human Erythropoietin</i> , 172 IMMUNOBIOLOGY 213 (1986), pp 213-224, 217-218, (1986)
Exhibit SS	October 23, 1987, Declaration Pursuant to 37 C.F.R. § 1.132, 113,178
Exhibit TT	WEBSTER'S II DICTIONARY (3d ed. 2005).
Exhibit UU	Expert Declaration of Patrick P. Deluca, Ph.D., and attached exhibits.

03099/00501 644853.1